Pharmaceutical product branding strategies: Simulating patient flow and portfolio dynamics

Pharmaceutical Product Branding Strategies: Simulating Patient Flow and Portfolio Dynamics

Volumn , Issue , 2009, Pages 1-295

  Paich, Mark ^a   Peck, Corey ^b   Valant, Jason ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988333405     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420087710     Document Type: Book

References (56)

1. Kessler RC, Lane M, Stang PE, et al. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med. 2008;21:1-11.
2. Willey C, Faraone SV, Peterson S, et al. A dynamic patient flow model to identify areas to improve awareness and diagnosis in adults with attention deficit hyperactivity disorder. Poster presented at the 2008 American Psychiatric Association Annual Meeting, Washington, D.C., May 3-8, 2008.
3. Faraone SV, Willey C, Peterson S, Stafford J. Diagnosis of Adult Attention Deficit Hyperactivity Disorder: Experimental Results From the Adult ADHD Patient Flow Model. Poster presented at the 2008 American Psychiatric Association Annual Meeting, Washington, D.C., May 3-8, 2008.
4. Richmond B, Peterson S. An Introduction to Systems Thinking. From the Users Manuals for the iThink Software. Lebanon, NH: Available from iseesystems, Inc., 1996.
5. Lilien G, Kotler P, Moorthy KS. Marketing Models. Englewood Cliffs, NJ: Prentice- Hill, 1992.
6. Forester JW. Industrial Dynamics. Cambridge, MA: MIT Press, 1961.
7. Richmond B, Peterson S. An Introduction to Systems Thinking. From the users manuals for the ithink software. Lebanon, NH: Available from iseesystems, Inc., 1996.
8. Warren K. Competitive Strategy Dynamics. Chichester, UK: John Wiley & Sons, 2002.
9. Gladwell M. Tipping Point: How Little Thing Can Make A Big Difference. Boston, MA: Back Bay Books, 2002.
10. Sterman J. Business Dynamics: Systems Thinking and Modeling for a Complex World. Boston, MA: McGraw Hill, 2002.
11. Improving Chronic Illness Care-A National Project of the Robert Wood Johnson Foundation. http://www.improvingchroniccare.org
12. Chronic Illness Coalition. http://www.home.tir.com/~slater/id1.html.
13. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: general information and national estimates on diabetes in the United States, 2003. Revised edition. Atlanta, GA. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.
14. Rasiel EM. The McKinsey Way: Using the Techniques of the World's Top Strategic Consultants to Help You and Your Business. New York, NJ. McGraw-Hill, 1999.
15. Sweeney LB, Sterman JD. Bathtub Dynamics: Initial Results of a Systems Thinking Inventory. Working paper, v. 1.2. September, 2000. Forthcoming, System Dynamics Review. http://www.web.mit.edu/jsterman/www/bathtub.
16. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24(11):1936-1940.
17. Bernstein PL. Against The Gods: The Remarkable Story of Risk. John Wiley & Sons, 1998:74-87.
18. Simon F, Kotler P. Building Global Biobrands: Taking Biotechnology to Market. New York, NY: Simon & Schuster, 2003.
19. American Heart Association. Heart Disease and Stroke Statistics-Final 2004 data. Dallas, TX: American Heart Association, 2008.
20. American Heart Association. 2008 Update. http://www.americanheart.org.
21. United Network for Organ Sharing. http://www.unos.org; The Organ Procurement and Transplant Network. http://www.optn.org.
22. American Academy of Orthopaedic Surgery. http://www.aaos.org.
23. Lilien G, Kotler P, Moorthy KS. Marketing Models. Englewood Cliffs, NJ: Prentice- Hill, 1992.
24. American Stroke Association. http://www.strokeassociation.org.
25. Gagnon MA, Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008; 5(1).
26. Liebman M. Finally, Predictive Returns on Promotional Investments. Medical Marketing and Media, 1998.
27. Berndt E, Pindyck R. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs, NBER working paper No. 7024, March 1999.
28. Zoltners A, Hahn M, Park S, et al. Analysis of New Product Diffusion Using a Four- Segment Trial Repeat Model", Marketing Science, Summer 1994.
29. Sterman J. Business Dynamics: Systems Thinking and Modeling for a Complex World. Boston, MA: McGraw Hill, 2002.
30. Moore G. Crossing the Chasm: Marketing and Selling High-Tech Products to Mainstream Customers. HarperBusiness, 1999.
31. The Organ Procurement and Transplant Network, 2008. http://www.optn.org.
32. Cook, Arthur G. Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them. Aldershot, Hampshire, England: Gower Publishing, 2006.
33. Lilien G, Kotier P, Moorthy KS. Marketing Models. Englewood Cliffs, NJ: Prentice- Hill, 1992.
34. Rust R, Lemon K, Zeithaml V. Driving Customer Equity: Linking Customer Lifetime Value to Strategic Marketing Decisions. Marketing Science Institute Working Paper 01-108, 2001.
35. Ding M, Eliashberg J. Structuring the New Product Development Pipeline, Management Science, March 2002.
36. Berndt E, Pindyck R. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. NBER working paper No. 7024, March 1999.
37. Zoltners A, Hahn M, Park S, et al. Analysis of New Product Diffusion Using a Four- Segment Trial Repeat Model. Marketing Science, Summer 1994.
38. Berndt E, Pindyck R. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. NBER working paper No. 7024, March 1999.
39. Berndt E, Pindyck R. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. NBER working paper No. 7024, March 1999.
40. Brandenburger A, Nalebuff B. Co-opetition: A Revolution Mindset That Combines Competition and Cooperation, The Game Theory Strategy That's Changing the Game of Business. Doubleday, 1997.
41. Arthur WB. Increasing Returns and Path Dependence in the Economy. Ann Arbor, MI: University of Michigan Press, 1994.
42. Sterman J. Business Dynamics: Systems Thinking and Modeling for a Complex World Boston, MA: McGraw Hill, 2002.
43. Bonabeau E. Predicting the unpredictable. Harvard Business Review, March 2002.
44. Vennix JAM. Group Model Building. Chichester, UK: John Wiley, 1996.
45. Zoltners A, Hahn M, Park S, et al. Analysis of New Product Diffusion Using a Four-Segment Trial Repeat Model. Marketing Science, Summer 1994.
46. Berndt E, Pindyck R. Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs. NBER working paper No. 7024, March 1999.
47. Golan A, Judge G, Miller D. Maximum Entropy Econometrics: Robust Estimation with Limited Data. John Wiley, 1996.
48. OptQuest for Crystal Ball 2000, Users Manual, Decisioneering, Inc.
49. Trigeorgis L. Real Options and Business Strategy. Risk Books, 1999.
50. Schwartz E. Evaluating Investments in Disruptive Technologies. UCLA Anderson School of Management, May 2001.
51. Bankes S, Lempert R, Popper S. Shaping the Next One Hundred Years. Rand Pardee Center, 2003.
52. Savage LJ. The Foundation of Statistics. John Wiley, 1950.
53. Homer J. A Dynamic Model for analyzing the emergence of new Medical technologies. PhD thesis, MIT Sloan School of Management, Unpublished.
54. Pharmaceutical Industry Profile 2002, Pharmaceutical Research and Manufacturers of America (PhRMA)
55. On Treacherous Ground, 50 of the world's biggest pharmaceutical companies are challenged to perform in the most difficult environment ever. Med Ad News, September 1, 2002.
56. By Learning From Failures, Lilly Keeps Drug Pipeline Full. Wall Street Journal, April 21, 2004.